

primary studies - published RCT

## **Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study.**

Code: PM22968159

Year: 2012 Date: 2016

Author: Furnari ML

### **Study design (if review, criteria of inclusion for studies)**

Randomized, double-blinded, placebo-controlled trial

### **Participants**

110 subjects (age 10.4 +/- 3.0 y)

### **Interventions**

LYM-X-SORB (LXS), an easily absorbable lipid matrix that enhances fat absorption

### **Outcome measures**

plasma fatty acids (FA), and coefficient of fat absorption (CFA)

### **Main results**

Total FA increased with LXS at 3 and 12 months (+1.58; +1.14 mmol/L) and not with placebo (P = 0.046). With LXS, linoleic acid (LA) increased at 3 and 12 months (+298; +175 nmol/mL, P

### **Authors' conclusions**

LXS treatment improved dietary fat absorption compared to placebo as indicated by plasma FA and LA and was associated with better growth status.

<http://dx.doi.org/10.1177/1753465812458984>

### **See also**

Ther Adv Respir Dis. 2012 Sep 11.

### **Keywords**

Child; Gastrointestinal Diseases; Lym-X-Sorb; non pharmacological intervention - diet; Pancreas insufficiency; Pancreatic Diseases; placebo; Malabsorption; Nutrition Disorders; Powders; Phosphatidylcholines; Gastrointestinal Agents; essential fatty acids;